Single Use Bioprocessing Market

Growing strategic partnerships and mergers are driving the market growth

Market CAGR for single use bioprocessing is being driven by the fact that strategically acquiring single-use technology can boost biopharmaceutical industry acceptance. Simplifying processes, cutting down on waste, and enhancing quality control are all made easier and more affordable with single-use technologies. In order to get a competitive edge in a crowded market, businesses should consider strategically obtaining high-quality single-use technologies. Increasing process visibility and control through the deliberate acquisition of single-use technology can lead to more openness and conformity with industry norms.

Companies that want to save money, work more efficiently, and gain an edge in the market often make deliberate purchases of single-use technologies. In addition, businesses are forming alliances to enter regional markets for one-time bioprocessing applications.

Additionally, new advances in technology have been crucial in the rollout of novel single-use bioprocess consumables around the world. Market participants in the field of single-use bioprocessing have released new solutions that make the practice far more secure, user-friendly, and productive. Companies have been able to increase their market share by adapting to these trends and needs. The increasing production and usage of biopharmaceuticals and bio-similar are the primary forces propelling the single-use bioprocessing industry. When it comes to manufacturing biopharmaceuticals, bio-therapeutics, vaccines, monoclonal antibodies, and bio-similar, single-use bioprocessing offers a highly advantageous platform.

However, it is expected that the high price of single use bioprocessing solutions will slow the expansion of the market. On the other hand, Due to potential effects on product quality and patient health, concerns about extractable and leachables originating from the components of single-use bioprocessing systems may impede market expansion.

The Global Single Use Bioprocessing Market Industry is poised for substantial growth, with projections indicating a market size of 15.0 USD Billion in 2024 and an anticipated expansion to 119.8 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate of 20.81% from 2025 to 2035, highlighting the increasing adoption of single-use technologies across the biopharmaceutical sector. The rising demand for efficient and flexible manufacturing solutions is likely to drive this growth, as companies seek to enhance their production capabilities. The market's evolution reflects broader trends in biomanufacturing, emphasizing the importance of innovation and adaptability in meeting future challenges.

The increasing focus on sustainability is emerging as a significant driver of the Global Single Use Bioprocessing Market Industry. As environmental concerns gain prominence, biopharmaceutical companies are seeking ways to minimize their ecological footprint. Single-use systems offer a more sustainable alternative to traditional bioprocessing methods by reducing water and energy consumption associated with cleaning and sterilization. This shift towards greener practices aligns with global sustainability goals and resonates with consumers and stakeholders alike. The market's growth trajectory, projected to reach 119.8 USD Billion by 2035, reflects the industry's commitment to sustainable practices and the adoption of eco-friendly technologies.

The increasing demand for biopharmaceuticals is a primary driver of the Global Single Use Bioprocessing Market Industry. As the global population ages and the prevalence of chronic diseases rises, the need for innovative therapies intensifies. In 2024, the market is projected to reach 15.0 USD Billion, reflecting the industry's response to these healthcare challenges. Single-use technologies facilitate rapid development and production of biopharmaceuticals, enabling companies to meet market demands efficiently. This trend is expected to continue, with the market potentially expanding to 119.8 USD Billion by 2035, indicating a robust growth trajectory fueled by the biopharmaceutical sector.

The cost-effectiveness of single-use systems significantly contributes to the expansion of the Global Single Use Bioprocessing Market Industry. These systems reduce the need for extensive cleaning and sterilization processes, thereby lowering operational costs for manufacturers. As companies seek to optimize their production processes, the adoption of single-use technologies becomes increasingly appealing. This trend is particularly relevant for small to mid-sized biopharmaceutical companies that may lack the resources for traditional bioprocessing methods. The anticipated compound annual growth rate of 20.81% from 2025 to 2035 underscores the financial advantages these systems offer, making them a preferred choice in the industry.

Technological advancements play a crucial role in shaping the Global Single Use Bioprocessing Market Industry. Innovations in materials and design of single-use systems enhance their functionality and reliability, leading to increased adoption across various applications. For instance, the development of advanced sensors and monitoring systems allows for real-time data collection, improving process control and efficiency. These advancements not only streamline production but also ensure compliance with stringent regulatory standards. As the industry evolves, the integration of cutting-edge technologies is likely to drive further growth, positioning single-use bioprocessing as a cornerstone of modern biomanufacturing.

Regulatory support for bioprocessing innovations is a pivotal factor influencing the Global Single Use Bioprocessing Market Industry. Governments and regulatory bodies are increasingly recognizing the benefits of single-use technologies in enhancing production efficiency and ensuring product safety. Initiatives aimed at streamlining regulatory processes for biopharmaceutical manufacturing encourage the adoption of single-use systems. This supportive environment fosters innovation and investment in the sector, ultimately contributing to market growth. As regulations evolve to accommodate new technologies, the industry is likely to witness accelerated adoption of single-use bioprocessing solutions, further solidifying their role in biomanufacturing.

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American single use bioprocessing market area will dominate this market because of several factors, including large-scale manufacturing units, rising disposable adoption, increasing healthcare spending, and a highly established healthcare infrastructure. The region's single-use bioprocessing market is also booming due to the prevalence of contract manufacturers and the widespread adoption of disposables within the industry.

Further, the major countries studied in the market report are The US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: SINGLE USE BIOPROCESSING MARKET SHARE BY REGION 2023 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe’s single use bioprocessing market accounts for the second-largest market share because of rising investments in R&D and production, widespread adoption of disposable products, rising healthcare costs, and a mature healthcare infrastructure. Further, the German single use bioprocessing market held the largest market share, and the UK single use bioprocessing market was the fastest-growing market in the European region.

The Asia-Pacific single use bioprocessing Market is predicted to grow at the highest CAGR from 2023 to 2032. This is because of the booming biopharmaceutical industry across the globe. Additionally, Asia Pacific is to start emerging as the pharmaceutical industry's production hub as a result of increased investments by biotechnology and pharmaceutical businesses and the rapid rise of contract manufacturers. Therefore, the area may play a crucial role in the development of the single-use bioprocessing market in the years to come.

Moreover, China’s single use bioprocessing market held the largest market share, and the Indian single use bioprocessing market was the fastest-growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the single use bioprocessing market grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the single use bioprocessing industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global single use bioprocessing industry to benefit clients and increase the market sector. In recent years, the single use bioprocessing industry has offered some of the most significant advantages to medicine. Major players in the single use bioprocessing market, including Thermo Fisher Scientific Inc., Sartorius AG, Merck KGaA, Pall Corporation, Corning Incorporated, Eppendorf AG, General Electric Company (GE Healthcare), Lonza, Rentschler Biopharma SE, JM BioConnect, Meissner Filtration Products, Inc., Infors AG, Boehringer Ingelheim GmbH, Entegris, Inc., and PBS Biotech Inc.

Akron BioProducts provides the premier cell and gene therapy products and services available today. In order to help advanced therapy developers speed up the process of bringing new medicines to market, Akron has earned ISO 13485 certification by adhering to cGMP criteria and international standards. In April 2022, Akron BioProducts, a leading manufacturer of cGMP-compliant materials and technology for cell and gene therapy manufacturing, released a new product line called Closed System Solutions, which is meant to seal off essential stages of production hermetically.

Merck is a well-known scientific and technological business that works in the fields of electronics, healthcare, and life sciences. By developing more happy and sustainable lifestyle options, more than 64,000 professionals strive to impact millions of people's lives every day positively. The company is widely recognized for its ability to create and manufacture drugs more quickly, find novel approaches to treating the most difficult ailments, and empower gadgets with intelligence.

In June 2023, Merck announced an expansion of its facility in Lenexa, Kansas, making it the company's largest dry powder cell culture media facility and Center of Excellence in North America. Expand capabilities with new lab space and 9,100 sq m of additional manufacturing space.